Trials / Unknown
UnknownNCT03563794
Efficacy and Safety of Vildagliptin Added to Continuous Subcutaneous Insulin Infusion in Uncontrolled Type 2 Diabetes
- Status
- Unknown
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 400 (estimated)
- Sponsor
- The First Affiliated Hospital of Xiamen University · Academic / Other
- Sex
- All
- Age
- 30 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The randomized, controlled clinical trial investigate the efficacy and safety of vildagliptin added to continuous subcutaneous insulin infusion in uncontrolled type 2 diabetes
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CSII+Vildagliptin | Vildagliptin(50mg b.i.d po.) will be added to Continuous Subcutaneous Insulin Infusion(insulin Lispro) treatment in T2DM. Doses of insulin Lispro will be instructed on a titration schedule, adjusted every 2 days. |
| DRUG | CSII(insulin Lispro) | T2DM patients will receive Continuous Subcutaneous Insulin Infusion(insulin Lispro) treatment. Doses of insulin Lispro will be instructed on a titration schedule, adjusted every 2 days. |
Timeline
- Start date
- 2018-06-10
- Primary completion
- 2019-06-10
- Completion
- 2019-12-10
- First posted
- 2018-06-20
- Last updated
- 2018-06-20
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03563794. Inclusion in this directory is not an endorsement.